Antiverse Ltd

Antiverse Ltd, based in the UK, specializes in innovative antibody design, utilizing advanced machine learning and engineering techniques to create therapeutics targeting complex drug targets. Founded in 2017 in Wales, UK, Antiverse Ltd focuses on developing target-specific antibody libraries. The company has evolved its strategies to enhance its capabilities in drug discovery, specifically addressing G-protein coupled receptors and ion channels. The company operates independently and was established by founders Murat Tunaboylu (CEO) and Ben Holland.

Antiverse has its most recent funding round in February 2026, raising USD 9. 3 million in series A funding from investors including Soulmates Ventures,DOMiNO Ventures and Innovation Investment Capital, Development Bank of Wales, i&i Bio, and Kadmos Capital. Antiverse specializes in the design of target-specific antibody libraries engineered to address complex drug targets, particularly G-protein coupled receptors and ion channels. By employing advanced machine learning techniques alongside cutting-edge cell line engineering, Antiverse creates innovative de novo antibody therapeutics.

The company aims to enhance the efficiency of the antibody discovery process, enabling clients to identify functional binders within a six-month timeframe. Its primary clients are global pharmaceutical companies, particularly in North America and Europe, where the demand for advanced therapeutic solutions is significant. Antiverse generates revenue through strategic partnerships and collaborations with leading pharmaceutical companies. The business model primarily involves B2B transactions structured around tailored programs to meet specific client needs.

It earns revenue from the provision of antibody design services, which encompass various phases of drug development including custom antibody libraries and validation processes. Antiverse engages in project-based contracts with clients, negotiating based on the complexity of specific projects, focusing on delivering scientifically driven results. The company will use the February 2026 funding to support its growth and further development of its AI-powered antibody discovery platform.